Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
abacavir/dolutegravir/lamiVUDine
abacavir/dolutegravir/lamiVUDine
Hazardous Drugs
Handling Guide (Group 2: Non-Antineoplastic)
Cell Status
NFISA
Brand names:
TRIUMEQ
Form
Strength
TABLET, ORAL
600 mg-50 mg-300 mg
Additional Information:
MAY 2022 P&T MINUTES
Last updated:
Mar. 10, 2023
Black Box Warning:
Hypersensitivity Reactions, Lactic Acidosis and Severe Hepatomegaly; Exacerbations of Hepatitis B
FDA Drug Safety:
abacavir-FDA Drug Safety Communication: Safety Review update of Abacavir and possible increased risk of heart attack
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
MAY 2022 P&T MINUTES